References
- Barouch DH, Korber B. HIV-1 vaccine development after STEP. Annu. Rev. Med.61, 153–167 (2010).
- McElrath MJ. Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection. J. Infect. Dis.202(Suppl. 2), S323–S326 (2010).
- Watkins JD, Siddappa NB, Lakhashe SK et al. An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS ONE6(3), e18207 (2011).
- Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med.361(23), 2209–2220 (2009).
- Bomsel M, Tudor D, Drillet AS et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity34(2), 269–280 (2011).
- Ferrari G, Pollara J, Kozink D et al. A HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 Conformational epitope mediates potent ADCC activity and defines a common ADCC epitope in human HIV-1 serum. J. Virol.85(14), 7029–7036 (2011).
- Barassi C, Lazzarin A, Lopalco L. CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. Blood104(7), 2205–2206 (2004).
- Devito C, Broliden K, Kaul R et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J. Immunol.165(9), 5170–5176 (2000).
- Tudor D, Derrien M, Diomede L et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol.2(5), 412–426 (2009).
- Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol.6(2), 148–158 (2006).
- Donadoni C, Bisighini C, Scotti L et al. Setting of methods for analysis of mucosal antibodies in seminal and vaginal fluids of HIV seropositive subjects from Cambodian and Italian cohorts. PLoS ONE5(3), e9920 (2010).
- Coutant J, Yu H, Clément MJ et al. Both lipid environment and pH are critical for determining physiological solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1. FASEB J.22(12), 4338–4351 (2008).
- Visciano ML, Diomede L, Tagliamonte M et al. Generation of HIV-1 virus-like particles expressing different HIV-1 glycoproteins. Vaccine29(31), 4903–4912 (2011).
- Clerici M, Barassi C, Devito C et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the α-helix of gp41. AIDS16(13), 1731–1741 (2002).
- Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol.22(3), 358–366 (2010).
- Barouch DH, O’Brien KL, Simmons NL et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med.16(3), 319–323 (2010).
- Hladik F, Hope TJ. HIV infection of the genital mucosa in women. Curr. HIV/AIDS Rep.6(1), 20–28 (2009).
- Lindqvist M, Persson J, Thörn K, Harandi AM. The mucosal adjuvant effect of α-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J. Immunol.182(10), 6435–6443 (2009).
- Lopalco L. CCR5: from natural resistance to a new anti-HIV strategy. Viruses2, 574–600 (2010).
- Lopalco L. Natural anti-CCR5 antibodies in HIV-infection and -exposure. J. Transl. Med.9(Suppl. 1), S4 (2010).